Aditxt Inc. (ADTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aditxt Inc. (ADTX) has a cash flow conversion efficiency ratio of 0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.58 Million) by net assets ($-35.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aditxt Inc. (ADTX) net asset quality to measure how much of total assets are equity-financed.
Aditxt Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Aditxt Inc. 's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ADTX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Aditxt Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aditxt Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SDM SE INH O.N.
F:75S
|
N/A |
|
SDM SE
XETRA:75S
|
0.321x |
|
Taiwan Styrene Monomer Corp
TW:1310
|
-0.031x |
|
SOL GLOBAL INVESTM. CORP
F:9SB
|
0.233x |
|
Hannun SA
MC:HAN
|
-113.815x |
|
Bank JTrust Indonesia Tbk PT
JK:BCIC
|
-0.086x |
|
Landsea Homes Corporation
NASDAQ:LSEAW
|
-0.015x |
|
Binh Duong Construction & Civil Engineering JSC
VN:BCE
|
N/A |
Annual Cash Flow Conversion Efficiency for Aditxt Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Aditxt Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see ADTX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.95 Million | $-25.69 Billion | -6497.326x | -321096.90% |
| 2024-12-31 | $8.29 Million | $-16.76 Million | -2.023x | -74.73% |
| 2023-12-31 | $16.05 Million | $-18.58 Million | -1.158x | +73.08% |
| 2022-12-31 | $5.21 Million | $-22.39 Million | -4.301x | -96.55% |
| 2021-12-31 | $10.18 Million | $-22.28 Million | -2.188x | -233.69% |
| 2020-12-31 | $11.01 Million | $-7.22 Million | -0.656x | -502.79% |
| 2019-12-31 | $-2.85 Million | $-464.35K | 0.163x | -35.23% |
| 2018-12-31 | $-1.54 Million | $-386.26K | 0.251x | -96.10% |
| 2017-12-31 | $-59.90K | $-386.26K | 6.448x | -- |
About Aditxt Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body nat… Read more